Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | GPX4 | P36969 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113571 | 0.92 | KDM4E (0.34) | ALDH1A1KDM4EMAPTSMN1; SMN2MCL1 | |
| SCHEMBL4113581 | 0.92 | KDM4E (0.34) | ALDH1A1KDM4EMAPTSMN1; SMN2MCL1 | |
| SCHEMBL13775240 | 0.87 | FDFT1 (0.39) | NR1H4ALDH1A1KDM4EGAAMAPT | |
| SCHEMBL13775454 | 0.86 | KDM4E (0.34) | NR1H4ALDH1A1KDM4EMAPTHTT | |
| SCHEMBL13775445 | 0.86 | GAA (0.40) | NR1H4GPX4ALDH1A1KDM4EJAK2 | |
| SCHEMBL13775457 | 0.85 | NR1H4 (0.36) | NR1H4GPX4ALDH1A1KDM4EGAA | |
| SCHEMBL13775447 | 0.84 | NR1H4 (0.33) | NR1H4KDM4EMMP1 | |
| SCHEMBL4123855 | 0.82 | FDFT1 (0.37) | NR1H4ALDH1A1KDM4EMAPT | |
| SCHEMBL4123861 | 0.82 | FDFT1 (0.37) | NR1H4ALDH1A1KDM4EMAPT | |
| SCHEMBL13775726 | 0.80 | KRAS (0.37) | NR1H4GPX4ALDH1A1KDM4EJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | NR1H4 179/4885GPX4 2456/4885ALDH1A1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.